AGENUS INC (AGEN): Nasdaq/NYSE listing notice — Agenus receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure

AGENUS INC

On Dec 4, 2023, Nasdaq notified Agenus that its common stock's closing bid price was below $1.00 for 31 consecutive business days.
Company has until June 3, 2024 to regain compliance by maintaining a $1.00+ closing bid price for 10 consecutive business days.
If not cured by June 3, Agenus may be eligible for an additional 180-day extension subject to meeting other listing standards.
Company is confident in resolving the deficiency; reverse stock split is under consideration but not the primary focus.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

AGENUS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 4, 2023, Agenus Inc. (the “Company") was notified by the Nasdaq Stock Market's Listing Qualifications Department that the Company’s common stock's closing bid price had not met the $1.00 minimum bid price requirement for 31 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). This situation, however, will not impact the listing of the Company's common stock on the Nasdaq Capital Market for a minimum of 180 days with the possibility of an extension of another 180 days. The Company has been granted an initial automatic 180-day period, ending on June 3, 2024, to rect

View on SEC.gov

Browse all listing & compliance notices →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-069051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.